First phase III trial of Zactima in NSCLC completes enrollment

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.